Correlation Between LMF Acquisition and Virax Biolabs

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both LMF Acquisition and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining LMF Acquisition and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between LMF Acquisition Opportunities and Virax Biolabs Group, you can compare the effects of market volatilities on LMF Acquisition and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in LMF Acquisition with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of LMF Acquisition and Virax Biolabs.

Diversification Opportunities for LMF Acquisition and Virax Biolabs

-0.12
  Correlation Coefficient

Good diversification

The 3 months correlation between LMF and Virax is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding LMF Acquisition Opportunities and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and LMF Acquisition is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on LMF Acquisition Opportunities are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of LMF Acquisition i.e., LMF Acquisition and Virax Biolabs go up and down completely randomly.

Pair Corralation between LMF Acquisition and Virax Biolabs

Considering the 90-day investment horizon LMF Acquisition Opportunities is expected to generate 0.77 times more return on investment than Virax Biolabs. However, LMF Acquisition Opportunities is 1.29 times less risky than Virax Biolabs. It trades about 0.04 of its potential returns per unit of risk. Virax Biolabs Group is currently generating about -0.03 per unit of risk. If you would invest  209.00  in LMF Acquisition Opportunities on December 26, 2024 and sell it today you would earn a total of  12.00  from holding LMF Acquisition Opportunities or generate 5.74% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

LMF Acquisition Opportunities  vs.  Virax Biolabs Group

 Performance 
       Timeline  
LMF Acquisition Oppo 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in LMF Acquisition Opportunities are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent fundamental indicators, LMF Acquisition unveiled solid returns over the last few months and may actually be approaching a breakup point.
Virax Biolabs Group 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

LMF Acquisition and Virax Biolabs Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with LMF Acquisition and Virax Biolabs

The main advantage of trading using opposite LMF Acquisition and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if LMF Acquisition position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.
The idea behind LMF Acquisition Opportunities and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device